Person:

Hong, Soyon

Despite intense therapeutic and diagnostic focus on dyshomeostasis of amyloid (\beta)-peptide ((A\beta)) in Alzheimer’s disease (AD), we still lack insight into the in vivo economy of (A\beta) in the normal and diseased brain. Thus, my thesis research focused on understanding the dynamics of (A\beta) in the living brain during the development of AD-type pathology. Using in vivo microdialysis, I showed that the steady-state level of (A\beta) that remains diffusible in the hippocampal interstitial fluid (ISF) of awake, behaving hAPP transgenic mice falls as (A\beta) steadily accumulates in the brain parenchyma. In accord, I observed distinct dispositions of microinjected radiolabeled (A\beta) in plaque-rich versus plaque-free mice, suggesting that cerebral amyloid deposits rapidly sequester newly released (A\beta). This provides the first in vivo evidence from controlled animal experiments for the hypothesis that soluble (A\beta42) in human cerebrospinal fluid (CSF) falls in AD because it is sequestered into insoluble parenchymal deposits as the disease develops. My data further show that the association of (A\beta) with insoluble parenchymal deposits is not irreversible, as acute inhibition of (\gamma)-secretase in plaque-rich mice failed to lower ISF (A\beta42), whereas it did in plaque-free mice. Hence, the ISF in plaque-rich mice seems to be a reservoir for both newly produced (A\beta) and (A\beta) that diffuse off of cell membrane- and plaque-bound deposits. Finally, I showed that (A\beta) dimers, which are known to be potent synaptic neurotoxins, are undetectable in the aqueous compartments of the central nervous system, i.e., the brain ISF and CSF, in hAPP transgenic mice. Acute injection of (A\beta) dimers into living wild-type mice showed a rapid sequestration of the dimers away from the hippocampal ISF pool and a higher recovery in the membrane-bound pool than in the cytosolic pool of the brain homogenates. Interestingly, I found that the (A\beta) recovered in the membrane-bound pool was tightly associated with endogenous GM1 ganglioside. Taken together, my results suggest that (A\beta) dimers, and probably higher oligomers, are rapidly sequestered away from the ISF and bind to GM1 ganglioside-enriched lipid membranes, such as raft-like microdomains of secreted vesicles or on the plasma membranes of neurons and other cells.

Many single-transmembrane proteins are sequentially cleaved by ectodomain-shedding α-secretases and the γ-secretase complex, a process called regulated intramembrane proteolysis (RIP). These cleavages are thought to be spatially and temporally separate. In contrast, we provide evidence for a hitherto unrecognized multiprotease complex containing both α- and γ-secretase. ADAM10 (A10), the principal neuronal α-secretase, interacted and cofractionated with γ-secretase endogenously in cells and mouse brain. A10 immunoprecipitation yielded γ-secretase proteolytic activity and vice versa. In agreement, superresolution microscopy showed that portions of A10 and γ-secretase colocalize. Moreover, multiple γ-secretase inhibitors significantly increased α-secretase processing (r = −0.86) and decreased β-secretase processing of β-amyloid precursor protein. Select members of the tetraspanin web were important both in the association between A10 and γ-secretase and the γ→α feedback mechanism. Portions of endogenous BACE1 coimmunoprecipitated with γ-secretase but not A10, suggesting that β- and α-secretases can form distinct complexes with γ-secretase. Thus, cells possess large multiprotease complexes capable of sequentially and efficiently processing transmembrane substrates through a spatially coordinated RIP mechanism.